RSS

Bristol–Myers Squibb

Biopharmaceutical companies, AbbVie and Bristol-Myers Squibb, have announced the formation of a clinical research collaboration to evaluate a combination therapeutic regimen for the treatment of advanced solid tumours. more

News

Opdivo, also known as nivolumab, will now be available to NHS patients suffering from lung cancer as the drug’s manufacturer, Bristol-Myers Squibb, offers the National Institute for Health and Care Excellence (NICE) a new cancer drugs fund (CDF) deal more

News

A clinical collaboration between Bristol-Myers Squibb and Clovis Oncology has been announced, which will evaluate the combination of Opdivo (nivolumab) and Rubraca (rucaparib) in Phase II and III trials for multiple tumour types. more

News

Abbvie, Sanofi and Novo Nordisk seens as most reputable pharma companies in the UK and industry as a whole ranked third most reputable by general public more

News

Merck and Pfizer’s medication for renal cell carcinoma (RCC) is the most likely immunotherapy combination to first arrive in market, according to Global Data more

News

Bristol-Myers Squibb (BMS) and Merck are set to continue their strong rivalry in the head and neck cancer space, according to GlobalData more

News

Bristol-Myers Squibb has selected Medidata’s Clinical Cloud to help manage, monitor and analyse its clinical trials data more

News

University of Leeds researchers are part of the £20.4m Advanced Digital Design of Pharmaceutical Therapeutics (ADDoPT) programme introducing digital design processes to the pharmaceutical industry more

News

As part of the agreement, BMS and Ono will jointly develop and commercialise Opdivo (nivolumab) and Yervoy (ipilimumab) across a broad range of tumour types. more

Recipharm has announced that its sixth International Environmental Award has been awarded to Ludwig Metz, Associate Director Environmental, Health & Safety, at pharmaceutical company Bristol–Myers Squibb. more

Technology